Cargando…

Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer

Mesoporous silicon nanoparticles (PSi NPs) are promising platforms of nanomedicine because of their good compatibility, high payload capacities of anticancer drugs, and easy chemical modification. Here, PSi surfaces were functionalized with bisphosphonates (BP) for radiolabeling, loaded with doxorub...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Huang, Poutiainen, Pekka, Batnasan, Enkhzaya, Latonen, Leena, Lehto, Vesa-Pekka, Xu, Wujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610067/
https://www.ncbi.nlm.nih.gov/pubmed/37896267
http://dx.doi.org/10.3390/pharmaceutics15102507
_version_ 1785128164104601600
author Wen, Huang
Poutiainen, Pekka
Batnasan, Enkhzaya
Latonen, Leena
Lehto, Vesa-Pekka
Xu, Wujun
author_facet Wen, Huang
Poutiainen, Pekka
Batnasan, Enkhzaya
Latonen, Leena
Lehto, Vesa-Pekka
Xu, Wujun
author_sort Wen, Huang
collection PubMed
description Mesoporous silicon nanoparticles (PSi NPs) are promising platforms of nanomedicine because of their good compatibility, high payload capacities of anticancer drugs, and easy chemical modification. Here, PSi surfaces were functionalized with bisphosphonates (BP) for radiolabeling, loaded with doxorubicin (DOX) for chemotherapy, and the NPs were coated with cancer cell membrane (CCm) for homotypic cancer targeting. To enhance the CCm coating, the NP surfaces were covered with polyethylene glycol prior to the CCm coating. The effects of the BP amount and pH conditions on the radiolabeling efficacy were studied. The maximum BP was (2.27 wt%) on the PSi surfaces, and higher radiochemical yields were obtained for (99m)Tc (97% ± 2%) and (68)Ga (94.6% ± 0.2%) under optimized pH conditions (pH = 5). The biomimetic NPs exhibited a good radiochemical and colloidal stability in phosphate-buffered saline and cell medium. In vitro studies demonstrated that the biomimetic NPs exhibited an enhanced cellular uptake and increased delivery of DOX to cancer cells, resulting in better chemotherapy than free DOX or pure NPs. Altogether, these findings indicate the potential of the developed platform for cancer treatment and diagnosis.
format Online
Article
Text
id pubmed-10610067
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106100672023-10-28 Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer Wen, Huang Poutiainen, Pekka Batnasan, Enkhzaya Latonen, Leena Lehto, Vesa-Pekka Xu, Wujun Pharmaceutics Article Mesoporous silicon nanoparticles (PSi NPs) are promising platforms of nanomedicine because of their good compatibility, high payload capacities of anticancer drugs, and easy chemical modification. Here, PSi surfaces were functionalized with bisphosphonates (BP) for radiolabeling, loaded with doxorubicin (DOX) for chemotherapy, and the NPs were coated with cancer cell membrane (CCm) for homotypic cancer targeting. To enhance the CCm coating, the NP surfaces were covered with polyethylene glycol prior to the CCm coating. The effects of the BP amount and pH conditions on the radiolabeling efficacy were studied. The maximum BP was (2.27 wt%) on the PSi surfaces, and higher radiochemical yields were obtained for (99m)Tc (97% ± 2%) and (68)Ga (94.6% ± 0.2%) under optimized pH conditions (pH = 5). The biomimetic NPs exhibited a good radiochemical and colloidal stability in phosphate-buffered saline and cell medium. In vitro studies demonstrated that the biomimetic NPs exhibited an enhanced cellular uptake and increased delivery of DOX to cancer cells, resulting in better chemotherapy than free DOX or pure NPs. Altogether, these findings indicate the potential of the developed platform for cancer treatment and diagnosis. MDPI 2023-10-22 /pmc/articles/PMC10610067/ /pubmed/37896267 http://dx.doi.org/10.3390/pharmaceutics15102507 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wen, Huang
Poutiainen, Pekka
Batnasan, Enkhzaya
Latonen, Leena
Lehto, Vesa-Pekka
Xu, Wujun
Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer
title Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer
title_full Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer
title_fullStr Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer
title_full_unstemmed Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer
title_short Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer
title_sort biomimetic inorganic nanovectors as tumor-targeting theranostic platform against triple-negative breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610067/
https://www.ncbi.nlm.nih.gov/pubmed/37896267
http://dx.doi.org/10.3390/pharmaceutics15102507
work_keys_str_mv AT wenhuang biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer
AT poutiainenpekka biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer
AT batnasanenkhzaya biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer
AT latonenleena biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer
AT lehtovesapekka biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer
AT xuwujun biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer